MCID: URN008
MIFTS: 63

Urinary Bladder Cancer

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Urinary Bladder Cancer

MalaCards integrated aliases for Urinary Bladder Cancer:

Name: Urinary Bladder Cancer 12 25 14
Bladder Cancer 12 50 25
Malignant Tumor of Urinary Bladder 25 29
Malignant Neoplasm of Urinary Bladder 69
Urinary Bladder Neoplasms 42
Cancer of the Bladder 25
Tumor of the Bladder 12
Carcinoma of Bladder 69
Bladder Neoplasm 69
Bladder Tumors 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11054
ICD10 33 C67 C67.9
ICD9CM 35 188 188.9
MeSH 42 D001749
NCIt 47 C2901 C9334

Summaries for Urinary Bladder Cancer

NIH Rare Diseases : 50 bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. most cases of bladder cancer occur sporadically in people with no family history of the condition. risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy. last updated: 11/11/2015

MalaCards based summary : Urinary Bladder Cancer, also known as bladder cancer, is related to prostate cancer and lung cancer. An important gene associated with Urinary Bladder Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Bladder cancer and ERK Signaling. The drugs Valstar and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and testes, and related phenotypes are homeostasis/metabolism and cellular

Disease Ontology : 12 An urinary system cancer that results_in malignant growth located in the urinary bladder.

Related Diseases for Urinary Bladder Cancer

Diseases related to Urinary Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 29.6 CDH1 CDKN1A ERBB2 GSTM1 KRAS KRT8
2 lung cancer 29.5 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
3 superficial urinary bladder cancer 12.2
4 bladder cancer, somatic 11.5
5 rectum squamous cell carcinoma 11.1 CDKN2A MDM2 TP53
6 vulva squamous cell carcinoma 11.1 CDKN2A ERBB2 KRT20
7 retinal detachment 11.1 CDKN2A KRT20 TP53
8 adenocarcinoma in situ 11.1 CDKN2A KRAS TP53
9 rnase t2-deficient leukoencephalopathy 11.1 MDM2 TP53
10 uterine corpus adenofibroma 11.1 KRAS KRT20 TP53
11 cervical adenoid cystic carcinoma 11.1 CDKN2A TP53
12 myotonia congenita 11.1 CDKN2A ERBB2 KRT20
13 villous adenocarcinoma 11.1 CDKN2A ERBB2 TP53
14 hypersensitivity reaction type iii disease 11.1 ERBB2 KRAS TP53
15 secondary pulmonary hemosiderosis 11.1 CDKN2A MDM2 TP53
16 migraine with aura 11.1 KRAS KRT20 TP53
17 spastic ataxia 3 11.1 CDKN2A KRT20 TP53
18 skeletal tuberculosis 11.1 CDKN2A ERBB2
19 bladder squamous cell carcinoma 11.1 CDKN2A MDM2 TP53
20 cavernous sinus thrombosis 11.1 KRAS KRT20 TP53
21 intrahepatic bile duct adenoma 11.1 FGFR3 KRT20 TERT TP53
22 juxtacortical chondrosarcoma 11.1 CDKN2A MDM2 RB1
23 extrahepatic bile duct adenoma 11.1 FGFR3 KRT20 TERT TP53
24 gorham's disease 11.1 ERBB2 FGFR3 KRAS
25 advanced sleep phase syndrome 11.1 CDKN2A KRAS TP53
26 acute cholinergic dysautonomia 11.1 CDKN1A MDM2 TP53
27 c-p angle neurinoma 11.1 CDKN2A MDM2 TP53
28 split hand split foot nystagmus 11.1 CDKN2A MKI67 TP53
29 juvenile astrocytoma 11.1 FGFR3 MDM2 TP53
30 lichen nitidus 11.1 CDKN1A MDM2 TP53
31 choriocarcinoma 11.1 CDKN2A KRT20 TP53
32 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 11.1 CDKN2A ERBB2 KRAS TP53
33 cecum adenocarcinoma 11.1 CDKN2A KRAS KRT20 TP53
34 pediatric infratentorial ependymoma 11.1 MKI67 TP53
35 adult spinal cord glioblastoma multiforme 11.1 ERBB2 KRT8
36 cervical neuroblastoma 11.1 ERBB2 KRAS TP53
37 emery-dreifuss muscular dystrophy, dominant type 11.1 GSTM1 GSTT1 NAT2
38 penis paget's disease 11.1 CDKN2A CDKN2B TP53
39 fasciolopsiasis 11.1 CDKN2A KRT20 TP53
40 heavy chain disease 11.1 CDKN2A KRT20 TP53
41 accessory nerve disease 11.1 CDKN2A MDM2 RB1 TP53
42 hip subluxation 11.1 ERBB2 MKI67 TP53
43 congenital hypomyelination neuropathy 11.1 KRAS NAT1 TP53
44 lacrimal gland mucoepidermoid carcinoma 11.1 CDH1 ERBB2 TP53
45 pancreatic signet ring cell adenocarcinoma 11.1 CDH1 KRT20 TP53
46 enamel hypoplasia cataract hydrocephaly 11.1 MDM2 MKI67 TP53
47 mycetoma 11.1 GSTM1 GSTT1 NAT2 TP53
48 plasmodium ovale malaria 11.1 CDKN2A MKI67 TP53
49 toxic megacolon 11.0 CDKN1A MDM2 TP53
50 peritoneal serous adenocarcinoma 11.0 CDH1 KRAS TP53

Comorbidity relations with Urinary Bladder Cancer via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Ischemic Heart Disease
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter Cancer Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Urinary Bladder Cancer:



Diseases related to Urinary Bladder Cancer

Symptoms & Phenotypes for Urinary Bladder Cancer

MGI Mouse Phenotypes related to Urinary Bladder Cancer:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
2 cellular MP:0005384 10.43 CDH1 CDKN1A RASSF1 RB1 TERT TP53
3 digestive/alimentary MP:0005381 10.38 ERBB2 FGFR3 KRAS KRT8 MDM2 RASSF1
4 endocrine/exocrine gland MP:0005379 10.37 KRAS MDM2 RASSF1 RB1 TERT TP53
5 cardiovascular system MP:0005385 10.36 KRT8 MDM2 RASSF1 RB1 TP53 TSC1
6 growth/size/body region MP:0005378 10.36 KRAS KRT8 MDM2 RB1 TERT TP53
7 mortality/aging MP:0010768 10.36 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
8 embryo MP:0005380 10.34 CDH1 CDKN1A CDKN2A ERBB2 KRAS KRT8
9 immune system MP:0005387 10.34 CDH1 CDKN1A CDKN2A CDKN2B FGFR3 KRAS
10 integument MP:0010771 10.29 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
11 neoplasm MP:0002006 10.29 CDKN2A CDKN2B ERBB2 FGFR3 KRAS MDM2
12 nervous system MP:0003631 10.2 CDKN2A ERBB2 FGFR3 KRAS MDM2 NAT1
13 liver/biliary system MP:0005370 10.18 CDKN1A CDKN2A KRAS KRT8 MDM2 RASSF1
14 craniofacial MP:0005382 10.16 CDKN1A ERBB2 FGFR3 KRAS MDM2 RB1
15 normal MP:0002873 10.14 CDH1 ERBB2 FGFR3 KRAS MDM2 MKI67
16 reproductive system MP:0005389 10.13 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
17 muscle MP:0005369 10.1 CDKN1A CDKN2A ERBB2 KRAS MDM2 RB1
18 no phenotypic analysis MP:0003012 10.09 CDH1 CDKN1A CDKN2A CDKN2B FGFR3 KRAS
19 limbs/digits/tail MP:0005371 10.08 CDKN1A ERBB2 FGFR3 KRAS MDM2 RB1
20 hearing/vestibular/ear MP:0005377 9.97 CDKN1A FGFR3 KRAS RB1 TP53
21 renal/urinary system MP:0005367 9.92 CDKN1A CDKN2B FGFR3 KRAS MDM2 RB1
22 respiratory system MP:0005388 9.81 CDKN1A CDKN2A ERBB2 FGFR3 KRAS RB1
23 pigmentation MP:0001186 9.77 CDKN2A KRAS MDM2 RB1 TP53
24 skeleton MP:0005390 9.65 TSC1 CDKN1A CDKN2A ERBB2 FGFR3 KRAS
25 vision/eye MP:0005391 9.23 FGFR3 KRAS NAT1 RB1 TP53 TSC1

Drugs & Therapeutics for Urinary Bladder Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Valstar 17 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for Urinary Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 521)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
4
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
5 Parecoxib Approved Phase 4 198470-84-7
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
8
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
11
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
12
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
15
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
16
Alverine Approved Phase 4 150-59-4 3678
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Lornoxicam Approved Phase 4 70374-39-9 5282204
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
21
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
24
Bethanechol Approved Phase 4 674-38-4 2370
25
B-Carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
26
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
27 tannic acid Approved, Nutraceutical Phase 4,Phase 2
28
BCG vaccine Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29
Fibrinolysin Investigational Phase 4 9004-09-5
30
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
31
Mebeverine Investigational Phase 4 3625-06-7 62887
32 Hemostatics Phase 4,Phase 2,Phase 3
33 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
37 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antioxidants Phase 4,Phase 3,Phase 2
41 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
46 Cholinergic Agents Phase 4,Phase 3,Phase 2
47 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
50 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1114)

id Name Status NCT ID Phase Drugs
1 Cost-Effectiveness in Bladder Cancer Unknown status NCT00126958 Phase 4
2 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
3 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
4 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
5 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
6 Parecoxib for Treatment of Catheter Related Bladder Discomfort Completed NCT02729935 Phase 4 Parecoxib;Placebo
7 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
8 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
9 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
10 Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT) Recruiting NCT02555163 Phase 4
11 Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer Recruiting NCT02214602 Phase 4 Epirubicin
12 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
13 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Recruiting NCT03039543 Phase 4 Rocuronium;Sugammadex
14 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
15 The Assessment of POCD After TURBT Under Spinal Anesthesia Recruiting NCT03029676 Phase 4 benzodiazepines;opioid
16 Investigation of Sugammadex in Outpatient Urological Procedures Recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
17 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Recruiting NCT03147599 Phase 4 Coloverin;Placebo
18 Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? Active, not recruiting NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
19 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Active, not recruiting NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
20 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Active, not recruiting NCT01661166 Phase 4 Fesoterodine
21 Peri-operative Aspirin Continuation Versus Discontinuation Enrolling by invitation NCT02350543 Phase 4 Aspirin
22 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer Not yet recruiting NCT03274284 Phase 4
23 "En Bloc" Resection of NMIBC: a Prospective, Single Centre,Randomized Study Not yet recruiting NCT03221062 Phase 4
24 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4 Praziquantel
25 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4 bethanechol chloride
26 VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate Terminated NCT01777217 Phase 4 Solifenacin succinate;Placebo
27 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
28 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
29 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
30 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
31 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
32 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
33 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
34 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
35 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
36 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
37 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3 distilled water
38 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unknown status NCT01469221 Phase 3 Apaziquone;Placebo
39 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
40 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
41 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
42 Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging Unknown status NCT01004211 Phase 3
43 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
44 Efficacy of Diclofenac BCG Irrigations Unknown status NCT01542567 Phase 3 Abitren;Placebo
45 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
46 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
47 Randomized Trial on Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
48 Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
49 URO-BCG-4 : Bladder Tumors Immunotherapy Completed NCT00213655 Phase 3
50 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3

Search NIH Clinical Center for Urinary Bladder Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Urinary Bladder Cancer

Genetic tests related to Urinary Bladder Cancer:

id Genetic test Affiliating Genes
1 Malignant Tumor of Urinary Bladder 29

Anatomical Context for Urinary Bladder Cancer

MalaCards organs/tissues related to Urinary Bladder Cancer:

39
Prostate, Lung, Testes, Kidney, Lymph Node, T Cells, Cervix

Publications for Urinary Bladder Cancer

Articles related to Urinary Bladder Cancer:

(show top 50) (show all 199)
id Title Authors Year
1
The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model. ( 28889385 )
2018
2
Perioperative Allogeneic Blood Transfusion Does Not Adversely Impact Oncological Outcomes After Radical Cystectomy for Urinary Bladder Cancer - a Propensity Score-weighted European Multicenter Study. ( 28905486 )
2017
3
Association between the TACC3 rs798766 Polymorphism and Risk of Urinary Bladder Cancer: A Synthesis Based on Current Evidence. ( 28655970 )
2017
4
The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients. ( 28668843 )
2017
5
Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. ( 28487862 )
2017
6
Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer. ( 28723884 )
2017
7
Overexpression of UHRF1 gene correlates with the major clinicopathological parameters in urinary bladder cancer. ( 28128913 )
2017
8
Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer. ( 28639914 )
2017
9
Urinary bladder cancer risk factors in an area of former coal, iron, and steel industries in Germany. ( 28696895 )
2017
10
The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. ( 28824948 )
2017
11
Urinary bladder cancer staging in CT urography using machine learning. ( 28786480 )
2017
12
Urinary bladder cancer in adults: a histopathological experience from Madinah, Saudi Arabia. ( 28065960 )
2017
13
A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-GuAcrin therapy for superficial urinary bladder cancer. ( 28677313 )
2017
14
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells. ( 28534961 )
2017
15
CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer. ( 28534984 )
2017
16
Highlight report: N-acetyltransferase 2 and urinary bladder cancer risk. ( 28577040 )
2017
17
Bayesian nonparametric areal wombling for small-scale maps with an application to urinary bladder cancer data from Connecticut. ( 28786130 )
2017
18
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1I+. ( 28263974 )
2017
19
Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. ( 28899722 )
2017
20
Outcome of urinary bladder cancer after combined therapies. ( 27453746 )
2016
21
Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. ( 27356691 )
2016
22
Unexpected Detection of Urinary Bladder Cancer on Dual Phase 18F-NaF PET/CT in a Patient With Back Pain. ( 27607180 )
2016
23
A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. ( 27512626 )
2016
24
Common Polymorphisms in GSTA1, GSTM1 and GSTT1 Are Associated with Susceptibility to Urinary Bladder Cancer in Individuals from Balkan Endemic Nephropathy Areas of Serbia. ( 27568660 )
2016
25
Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. ( 26733163 )
2016
26
Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. ( 27246180 )
2016
27
Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis. ( 27596295 )
2016
28
Functional polymorphisms in the IL6 gene promoter and the risk of urinary bladder cancer in India. ( 26605964 )
2016
29
mTOR inhibitors in urinary bladder cancer. ( 27235118 )
2016
30
Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. ( 27002743 )
2016
31
Nonmuscle-invasive and Muscle-invasive Urinary Bladder Cancer: Image Quality and Clinical Value of Reduced Field-of-view Versus Conventional Single-shot Echo-planar Imaging DWI. ( 26962794 )
2016
32
Outcome of urinary bladder cancer after combined therapies. ( 27974922 )
2016
33
[THE SOMATIC MUTATIONS AND ABERRANT METHYLATION AS POTENTIAL GENETIC MARKERS OF URINARY BLADDER CANCER]. ( 27455559 )
2016
34
Optical redox ratio and endogenous porphyrins in the detection of urinary bladder cancer: A patient biopsy analysis. ( 27714989 )
2016
35
A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. ( 27100215 )
2016
36
Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. ( 26382667 )
2016
37
Potential role of melastatin-related transient receptor potential cation channel subfamily M gene expression in the pathogenesis of urinary bladder cancer. ( 28101241 )
2016
38
Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. ( 26862849 )
2016
39
SiRNA-mediated silencing of Snail-1 induces apoptosis and alters micro RNA expression in human urinary bladder cancer cell line. ( 27322434 )
2016
40
Non-occupational Exposure to Agricultural Work and Risk of Urinary Bladder Cancer Among Egyptian Women. ( 27028960 )
2016
41
Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. ( 27376129 )
2016
42
Controversial roles played by toll like receptor 4 in urinary bladder cancer; A systematic review. ( 27316642 )
2016
43
CYP1B1 gene polymorphisms correlate with an increased risk of urinary bladder cancer in India. ( 26707614 )
2016
44
Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study. ( 26927070 )
2016
45
A Real-Time Non-invasive Auto-bioluminescent Urinary Bladder Cancer Xenograft Model. ( 27443377 )
2016
46
Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. ( 28025135 )
2016
47
Clinical value of digital image analysis in the diagnosis of urinary bladder cancer, particularly in aggressive tumors: a preliminary report. ( 27543866 )
2016
48
The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. ( 26631646 )
2016
49
Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer. ( 27446646 )
2016
50
Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study. ( 27797436 )
2016

Variations for Urinary Bladder Cancer

ClinVar genetic disease variations for Urinary Bladder Cancer:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
3 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
5 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
6 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
7 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
8 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic/Likely pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
9 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
10 TSC1 NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter) single nucleotide variant Pathogenic rs118203542 GRCh37 Chromosome 9, 135781440: 135781440
11 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 GRCh37 Chromosome 9, 135779172: 135779172
12 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic rs118203419 GRCh37 Chromosome 9, 135797205: 135797205
13 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic rs118203423 GRCh37 Chromosome 9, 135796824: 135796824

Expression for Urinary Bladder Cancer

Search GEO for disease gene expression data for Urinary Bladder Cancer.

Pathways for Urinary Bladder Cancer

Pathways related to Urinary Bladder Cancer according to KEGG:

37
id Name Kegg Source Accession
1 Bladder cancer hsa05219

Pathways related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
2
Show member pathways
12.82 CDKN1A CDKN2A KRAS MDM2 TP53
3
Show member pathways
12.77 CDKN1A ERBB2 FGFR3 KRAS MDM2 TP53
4 12.72 CDKN1A FGFR3 KRAS MDM2 RB1 TERT
5
Show member pathways
12.6 CDKN1A CDKN2A CDKN2B MDM2 RB1 TP53
6
Show member pathways
12.55 CDH1 ERBB2 KRAS MDM2 TP53
7 12.54 CDKN1A CDKN2A MDM2 MKI67 RB1 TP53
8
Show member pathways
12.53 ERBB2 FGFR3 KRAS TP53 TSC1
9
Show member pathways
12.48 ERBB2 FGFR3 KRAS MDM2 TP53
10 12.48 CDKN1A CDKN2A CDKN2B KRAS RB1 TERT
11 12.48 CDKN1A CDKN2A ERBB2 FGFR3 KRAS MDM2
12
Show member pathways
12.41 CDKN1A CDKN2A MDM2 RB1 TP53
13
Show member pathways
12.4 CDKN1A MDM2 TP53 TSC1
14 12.4 CDH1 CDKN1A CDKN2A CDKN2B MDM2 RB1
15
Show member pathways
12.39 CDKN1A CDKN2A CDKN2B RB1 TP53
16
Show member pathways
12.39 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
17
Show member pathways
12.34 CDKN1A ERBB2 KRAS MDM2 TP53
18 12.33 CDKN1A ERBB2 KRAS MDM2 TP53
19 12.31 CDKN1A MDM2 RB1 TP53
20 12.29 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3
21
Show member pathways
12.28 CDKN1A MDM2 RB1 TP53
22 12.28 CDKN1A CDKN2A CDKN2B KRAS MDM2 RB1
23
Show member pathways
12.24 CDKN1A CDKN2A CDKN2B RB1
24 12.21 CDH1 CDKN1A KRAS TP53
25 12.2 CDH1 KRAS MDM2 RB1 TP53 TSC1
26
Show member pathways
12.19 CDKN1A ERBB2 FGFR3 KRAS MDM2 RB1
27 12.12 CDKN1A CDKN2A KRAS MDM2 TP53 TSC1
28
Show member pathways
12.11 CDKN1A CDKN2B KRAS MDM2
29 12.1 CDKN1A CDKN2A MDM2 RB1 TP53
30 12.09 CDKN1A CDKN2B TERT TP53
31 12.09 CDKN1A MDM2 RB1 TP53
32 12.01 CDKN1A CDKN2A ERBB2 KRAS MDM2 TP53
33 12 CDKN1A CDKN2A MDM2 RB1 TP53
34 11.91 CDKN1A CDKN2A KRAS MDM2 RB1 TP53
35 11.88 CDKN1A MDM2 RB1 TP53
36 11.87 CDKN1A CDKN2B RB1 TP53
37
Show member pathways
11.84 CDKN1A MDM2 TP53
38 11.8 CDKN1A MDM2 TP53
39 11.76 CDKN1A KRT8 MKI67
40
Show member pathways
11.75 CDKN2A MDM2 TP53
41 11.74 CDKN1A CDKN2B ERBB2
42 11.73 ERBB2 FGFR3 KRAS TP53
43 11.66 CDKN1A CDKN2B ERBB2
44 11.64 MDM2 RASSF1 TP53
45 11.62 CDKN1A MDM2 RB1
46 11.6 CDKN2A MDM2 TP53
47 11.6 CDKN1A CDKN2A RB1 TP53
48 11.56 CDKN1A CDKN2A ERBB2 GSTM1 GSTT1 MDM2
49 11.54 CDKN1A KRAS RB1
50 11.52 CDKN1A CDKN2B MDM2 RB1 TP53

GO Terms for Urinary Bladder Cancer

Cellular components related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.8 CDKN1A CDKN2A CDKN2B ERBB2 GSTM1 GSTT1
2 cytoplasm GO:0005737 9.58 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3

Biological processes related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.87 CDKN1A CDKN2A CDKN2B MKI67 RASSF1 RB1
2 negative regulation of cell proliferation GO:0008285 9.85 CDKN1A CDKN2A CDKN2B RB1 TP53 TSC1
3 negative regulation of gene expression GO:0010629 9.84 CDKN1A MDM2 RB1 TERT
4 positive regulation of gene expression GO:0010628 9.81 ERBB2 KRAS MDM2 TP53
5 regulation of protein stability GO:0031647 9.73 CDKN2A KRAS TERT
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.7 CDKN1A MDM2 TP53
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.63 CDKN1A CDKN2B RB1
8 striated muscle cell differentiation GO:0051146 9.58 KRAS RB1
9 hepatocyte apoptotic process GO:0097284 9.58 KRT8 RB1
10 cellular response to gamma radiation GO:0071480 9.58 CDKN1A MDM2 TP53
11 positive regulation of cellular senescence GO:2000774 9.57 CDKN2A KRAS
12 negative regulation of immature T cell proliferation in thymus GO:0033088 9.49 CDKN2A ERBB2
13 signal transduction by p53 class mediator GO:0072331 9.48 CDKN1A TP53
14 replicative senescence GO:0090399 9.46 CDKN1A CDKN2A TERT TP53
15 cellular response to actinomycin D GO:0072717 9.43 MDM2 TP53
16 negative regulation of phosphorylation GO:0042326 9.43 CDKN1A CDKN2A CDKN2B
17 Ras protein signal transduction GO:0007265 9.43 CDKN1A CDKN2A KRAS RASSF1 RB1 TP53
18 amyloid fibril formation GO:1990000 9.25 MDM2
19 cell cycle arrest GO:0007050 9.17 CDKN1A CDKN2A CDKN2B RASSF1 RB1 TP53

Molecular functions related to Urinary Bladder Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 9.54 TERT TP53 TSC1
2 protein N-terminus binding GO:0047485 9.33 MDM2 TP53 TSC1
3 arylamine N-acetyltransferase activity GO:0004060 9.26 NAT1 NAT2
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CDKN1A CDKN2A CDKN2B
5 disordered domain specific binding GO:0097718 8.8 MDM2 RB1 TP53
6 protein binding GO:0005515 10.28 CDH1 CDKN1A CDKN2A CDKN2B ERBB2 FGFR3

Sources for Urinary Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....